Table 2. TCF-4 (TCF7L2) rs3814570 frequency distribution and statistical analysis of combined cohort samples.
| All | ||||||||||||
| controls | UC | CD (L1) | CD (L3) | CD (L1+L3) | CD (L2) | CD | IBD | controls | controls | |||
| n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | <> CD | <> UC | |||
| C<>T | CC<>CT+TT | C<>T | CC<>CT+TT | |||||||||
| rs3814570 | 1399 (100%) | 785 (100%) | 229 (100%) | 555 (100%) | 784 (100%) | 225 (100%) | 1009 (100%) | 1794 (100%) | 1.16; p = 0.02246 | 1.18; p = 0.04358 | 0.98; p = 0.78946 | 1.01; p = 0.94441 |
| Armitage's trend | Armitage's trend | |||||||||||
| C/C | 797 (56,97%) | 446 (56,82%) | 113 (49,34%) | 287 (51,71%) | 400 (51,02%) | 133 (59,11%) | 533 (52,82) | 979 (54,57%) | 1.15; p = 0.02852 | 0.97; p = 0.79641 | ||
| C/T | 488 (34,88%) | 282 (35,92%) | 94 (41,05%) | 209 (37,66%) | 303 (38,65%) | 73 (32,44%) | 376 (37,27%) | 658 (36,68%) | controls | controls | ||
| T/T | 114 (8,15%) | 57 (7,26%) | 22 (9,6%) | 59 (10,63%) | 81 (10,33%) | 19 (8,44%) | 100 (9,91%) | 157 (8,75%) | <> L1+L3 | <> L2 | ||
| C<>T | CC<>CT+TT | C<>T | CC<>CT+TT | |||||||||
| C | 2082 (74,41%) | 1174 (74,78%) | 320 (69,87%) | 783 (70,54%) | 1103 (70,34%) | 339 (75,33%) | 1442 (71,45%) | 2616 (72,91%) | 1.23; p = 0.00371 | 1.27; p = 0.00737 | 0.95; p = 0.67656 | 0.92; p = 0.54665 |
| T | 716 (25,59%) | 396 (25,22%) | 138 (30,13%) | 327 (29,46%) | 465 (29,66%) | 111 (24,67%) | 576 (28,54%) | 972 (27,09%) | Armitage's trend | Armitage's trend | ||
| 1.20; p = 0.00528 | 0.97; p = 0.68946 | |||||||||||
C<>T allele frequency difference.
CC<>CT+TT allele positivity; frequent homo vs heterozygous and rare homozygous.
The different distribution of genotypes is demonstrated for each group and subgroup: controls, inflammatory bowel disease (IBD), Crohn's disease (CD), ulcerative colitis (UC), CD with solely colonic involvement (L2) and CD with solely ileal (L1) as well as ileal and colonic involvement (L3). Differences in genotype distribution compared to controls in general as well as the amount of all carriers (allele positivity) were subject to t- tests in patients with UC, CD and the CD subgroups L2 as well as L1+L3. Finally, results of the Armitage's trend tests for verification of significant associations of the rare T- variant are shown.